These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 12540478)

  • 21. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity.
    Wang Y; Xin D; Liu K; Zhu M; Xiang J
    Bioconjug Chem; 2009 Dec; 20(12):2214-21. PubMed ID: 19950889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in the USP heparin monograph and implications for clinicians.
    Smythe MA; Nutescu EA; Wittkowsky AK
    Pharmacotherapy; 2010 May; 30(5):428-31. PubMed ID: 20411994
    [No Abstract]   [Full Text] [Related]  

  • 23. Linear diffusion of thrombin and factor Xa along the heparin molecule explains the effects of extended heparin chain lengths.
    Wagenvoord R; Al Dieri R; van Dedem G; Béguin S; Hemker HC
    Thromb Res; 2008; 122(2):237-45. PubMed ID: 18045667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid two-step synthesis of mitrin from heparosan: a replacement for heparin.
    Kuberan B; Beeler DL; Lawrence R; Lech M; Rosenberg RD
    J Am Chem Soc; 2003 Oct; 125(41):12424-5. PubMed ID: 14531682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles].
    Alban S
    Hamostaseologie; 2008 Feb; 28(1-2):51-61. PubMed ID: 18278163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity.
    Yoshitomi Y; Nakanishi H; Kusano Y; Munesue S; Oguri K; Tatematsu M; Yamashina I; Okayama M
    Cancer Lett; 2004 Apr; 207(2):165-74. PubMed ID: 15072825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. By increasing the affinity of heparin for fibrin, Zn(2+) promotes the formation of a ternary heparin-thrombin-fibrin complex that protects thrombin from inhibition by antithrombin.
    Chan HH; Leslie BA; Stafford AR; Roberts RS; Al-Aswad NN; Fredenburgh JC; Weitz JI
    Biochemistry; 2012 Oct; 51(40):7964-73. PubMed ID: 22978548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An anticoagulant activity system using nanoengineered autofluorescent heparin nanotubes.
    Cui W; Cui Y; Zhu P; Zhao J; Su Y; Yang Y; Li J
    Chem Asian J; 2012 Jan; 7(1):127-32. PubMed ID: 22028206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.
    Petitou M; Nancy-Portebois V; Dubreucq G; Motte V; Meuleman D; de Kort M; van Boeckel CA; Vogel GM; Wisse JA
    Thromb Haemost; 2009 Nov; 102(5):804-10. PubMed ID: 19888512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generation of "neoheparin" from E. coli K5 capsular polysaccharide.
    Lindahl U; Li JP; Kusche-Gullberg M; Salmivirta M; Alaranta S; Veromaa T; Emeis J; Roberts I; Taylor C; Oreste P; Zoppetti G; Naggi A; Torri G; Casu B
    J Med Chem; 2005 Jan; 48(2):349-52. PubMed ID: 15658847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dalteparin--another low-molecular-weight heparin.
    Med Lett Drugs Ther; 1995 Dec; 37(963):115-6. PubMed ID: 7500910
    [No Abstract]   [Full Text] [Related]  

  • 33. Designing fluorescent sensors of heparin.
    Sauceda JC; Duke RM; Nitz M
    Chembiochem; 2007 Mar; 8(4):391-4. PubMed ID: 17243186
    [No Abstract]   [Full Text] [Related]  

  • 34. Synthesis of thrombin-inhibiting heparin mimetics without side effects.
    Petitou M; Hérault JP; Bernat A; Driguez PA; Duchaussoy P; Lormeau JC; Herbert JM
    Nature; 1999 Apr; 398(6726):417-22. PubMed ID: 10201371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heparin-coated colloidal mesoporous silica nanoparticles efficiently bind to antithrombin as an anticoagulant drug-delivery system.
    Argyo C; Cauda V; Engelke H; Rädler J; Bein G; Bein T
    Chemistry; 2012 Jan; 18(2):428-32. PubMed ID: 22161774
    [No Abstract]   [Full Text] [Related]  

  • 36. New developments in the characterization of heparin and its impurities.
    Larive CK
    Anal Bioanal Chem; 2011 Jan; 399(2):525-6. PubMed ID: 21116617
    [No Abstract]   [Full Text] [Related]  

  • 37. [New medical anticoagulants].
    Choussat R; Montalescot G
    Rev Mal Respir; 1999 Nov; 16(5 Pt 2):985-95. PubMed ID: 10907447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthetic heparin.
    Linhardt RJ; Liu J
    Curr Opin Pharmacol; 2012 Apr; 12(2):217-9. PubMed ID: 22325855
    [No Abstract]   [Full Text] [Related]  

  • 39. Overview of the current procedures in synthesis of heparin saccharides.
    Zhao S; Zhang T; Kan Y; Li H; Li JP
    Carbohydr Polym; 2024 Sep; 339():122220. PubMed ID: 38823902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological rationale for the therapeutic role of specific antithrombins.
    Weitz JI
    Coron Artery Dis; 1996 Jun; 7(6):409-19. PubMed ID: 8889356
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.